Evidence map›Paper›PMID 38390463›Full record

ArticleOpen forum infectious diseases2024

Longitudinal Analysis of Mpox Virus DNA Detectability From Multiple Specimen Types During Acute Illness: A Cohort Study.

Darrell H S Tan, Oscar Pico Espinosa, John Matelski, Shreya S Khera, Attia Qamar, Reva Persaud, Jacklyn R Hurst, Angel Ly, Jessica Lam, Maedeh Naghibosadat and 10 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. From neglected to notoriety: a review of Mpox clinical features, virology, epidemiology, treatment and prevention strategies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Darrell H S TanDivision of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-3069-2875
Oscar Pico EspinosaMAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, Canada.
John MatelskiDivision of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada.
Shreya S KheraMAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, Canada.
Attia QamarScarborough Health Network, Scarborough, Ontario, Canada.
Reva PersaudMAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, Canada.
Jacklyn R HurstBiological Sciences, Sunnybrook Research Institute, Sunnybrook Hospital, Toronto, Ontario, Canada.
Angel LyToronto High Containment Facility, Temerty Medicine, University of Toronto, Toronto, Ontario, Canada.
Jessica LamToronto High Containment Facility, Temerty Medicine, University of Toronto, Toronto, Ontario, Canada.
Maedeh NaghibosadatBiological Sciences, Sunnybrook Research Institute, Sunnybrook Hospital, Toronto, Ontario, Canada.
Natasha ChristieToronto High Containment Facility, Temerty Medicine, University of Toronto, Toronto, Ontario, Canada.
Maan HassoPublic Health Ontario Laboratory, Toronto, Ontario, Canada.
Kevin GoughDivision of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada.
Linda R TaggartDivision of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada.
Charlie TanDivision of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada.
Mario OstrowskiDivision of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada.
Huiting MaMAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, Canada.
Scott D Gray-OwenToronto High Containment Facility, Temerty Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-1910-5614
Robert KozakBiological Sciences, Sunnybrook Research Institute, Sunnybrook Hospital, Toronto, Ontario, Canada.
Sharmistha MishraDivision of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada.
St. Michael's Hospital · CAUniversity of Toronto · CASunnybrook Hospital · CAPublic Health Ontario · CAThe Scarborough Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Longitudinal data on the detectability of monkeypox virus (MPXV) genetic material in different specimen types are scarce. Methods: We describe MPXV-specific polymerase chain reaction (PCR) results from adults with confirmed mpox infection from Toronto, Canada, including a cohort undergoing weekly collection of specimens from multiple anatomic sites until 1 week after skin lesions had fully healed. We quantified the time from symptom onset to resolution of detectable viral DNA (computed tomography [Ct] ≥ 35) by modeling exponential decay in Ct value as a function of illness day for each site, censoring at the time of tecovirimat initiation. Results: Among 64 men who have sex with men, the median (interquartile range [IQR]) age was 39 (32.75-45.25) years, and 49% had HIV. Twenty received tecovirimat. Viral DNA was detectable (Ct < 35) at baseline in 74% of genital/buttock/perianal skin swabs, 56% of other skin swabs, 44% of rectal swabs, 37% of throat swabs, 27% of urine, 26% of nasopharyngeal swabs, and 8% of semen samples. The median time to resolution of detectable DNA (IQR) was longest for genital/buttock/perianal skin and other skin swabs at 30.0 (23.0-47.9) and 22.4 (16.6-29.4) days, respectively, and shortest for nasopharyngeal swabs and semen at 0 (0-12.1) and 0 (0-0) days, respectively. We did not observe an effect of tecovirimat on the rate of decay in viral DNA detectability in any specimen type (all Conclusions: MPXV DNA detectability varies by specimen type and persists for over 3-4 weeks in skin specimens. The rate of decay did not differ by tecovirimat use in this nonrandomized study.

Indexed as

monkeypoxmpoxorthopoxviruspolymerase chain reactionprospective cohort studytecovirimat

Identifiers

PMID38390463
PMCPMC10883290
OpenAlexW4391593453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.